Health · 1 sources covering this

STAT+: Detailed data confirm Moderna and Merck cancer vaccine met key endpoints in melanoma trial

A Moderna and Merck personalized mRNA cancer vaccine reduced the risk of disease recurrence in patients with melanoma by 42% compared to standard treatment.

Share:X WhatsApp Reddit Facebook LinkedIn Open ↗

Coverage spectrum

0 L · 1 C · 0 R

How 1 sources are covering this

STATCenter·2h ago
STAT+: Detailed data confirm Moderna and Merck cancer vaccine met key endpoints in melanoma trial
A Moderna and Merck personalized mRNA cancer vaccine reduced the risk of disease recurrence in patients with melanoma by 42% compared to standard treatment.
Read at STAT →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://statesidedaily.com/embed/cluster/ec1d142414f355bf731ac3f879fad0185f321b4b"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="STAT+: Detailed data confirm Moderna and Merck cancer vaccine met key endpoints in melanoma trial"></iframe>

STAT+: Detailed data confirm Moderna and Merck cancer vaccine met key endpoints in melanoma trial

How 1 sources are covering this

STAT+: Detailed data confirm Moderna and Merck cancer vaccine met key endpoints in melanoma trial

More from Health

STAT+: AbbVie skin disorder drug succeeds in late-stage trial, but results miss market expectations

STAT+: Nutrition experts press White House to release ultra-processed food definition

Top MAHA adviser Calley Means resigns from White House days ahead of midterms

STAT+: Will the Treasury restrict U.S. investment in the Chinese biotech sector?

Reader

Trust & legal

Across the network